Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy

Canadian Journal of Gastroenterology

Volumn 24, Issue 10, 2010, Pages 588-592

  Sharzehi, Kaveh ^a   Huang, Mary Ann ^b   Schreibman, Ian R ^a   Brown, Kimberly A ^b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

Autoimmune liver disease; Difficult to treat; Mycophenolate

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BONE MARROW SUPPRESSION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 77958508170     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2010/891252     Document Type: Article

References (18)

1. Czaja AJ. Autoimmune liver disease. In: Walton RE, Boyer TB, eds. Hepatology: A Textbook of Liver Disease, vol 2, 4th edn. Philadelphia: Saunders, 2002:1163-94.
2. Czaja AJ. Autoimmune liver disease. Curr Opin Gastroenterol 2006;22:234-40.
3. Oo YH, Neuberger J. Use of mycophenolate in the treatment of autoimmune hepatitis. Liver Int 2005;25:687-91.
4. Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004;18:321-6.
5. Chatur N, Ramji A, Bain VG, et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: The Canadian Association for the Study of the Liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 2005;25:723-7. (Pubitemid 41038652)
6. Alvarez PA, Berg FB, Bianchi L, et al; International Autoimmune Hepatitis Group report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38.
7. Gordon FD, Simpson M. Use of immunomodulary agents is difficult in treating autoimmune hepatitis patients. J Clin Gastroenterol 2004;38:729-30. (Pubitemid 39274169)
8. Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004;38:805-9. (Pubitemid 39274185)
9. Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999;94:241-8.
10. Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, Taheri H, Kamalian N, Sotoudeh M. Cyclosporine A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001;46:1321-7. (Pubitemid 32523281)
11. Wiesner R, Rabkin J, Klintmalm G, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001;7:442-50. (Pubitemid 32492583)
12. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995;60:225-32.
13. Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: Comparison with conventional treatment for refractory disease. J Clin Gastroenterol 2005;39:819-25.
14. Brunt EM, Di Bisceglie AM. Histologic changes after the use of mycophenolate mofetil in autoimmune hepatitis. Human Pathol 2004;35:509-12.
15. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000;33:371-5.
16. van den Berg AP. Autoimmune hepatitis: Pathogenesis, diagnosis and treatment. Scand J Gastroenterol Suppl 1998;225:66-9.
17. Heneghan MA, Al-Chalabi T, McFarlane IG. Cost-effectiveness of pharmacotherapy for autoimmune hepatitis. Expert Opin Pharmacother 2006;7:145-56.
18. Czaja AJ, Bianchi FB, Carpenter HA, et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 2005;41:207-15.